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Abstract
Background: The effectiveness of cervical cancer screening programs is challenged by suboptimal participation
and coverage. Offering cervico-vaginal self-sampling for human papillomavirus testing (HPV self-sampling) to
non-participants can increase screening participation. However, the effect varies substantially among studies,
especially depending on the approach used to offer HPV self-sampling. The present trial evaluates the effect on
participation in an organized screening program of a HPV self-sampling kit mailed directly to the home of the
woman or mailed to the woman’s home on demand only, compared with the standard second reminder for
regular screening.
Methods/design: The CHOiCE trial is a parallel, randomized, controlled, open-label trial. It will include 9327 women
aged 30–64 years who are living in the Central Denmark Region and who have not participated in cervical cancer
screening after an invitation and one reminder. The women will be equally randomized into three arms: 1) Directly
mailed a second reminder including a HPV self-sampling kit; 2) Mailed a second reminder offering a HPV self-sampling
kit, to be ordered by e-mail, text message, phone, or through a webpage; and 3) Mailed a second reminder for
a practitioner-collected sample (control group). The primary outcome will be the proportion of women in the
intervention groups who participate by returning their HPV self-sampling kit or have a practitioner-collected sample
compared with the proportion of women who have a practitioner-collected sample in the control group at 90 and
180 days after mail out of the second reminders. Per-protocol and intention-to-treat analyses will be performed. The
secondary outcome will be the proportion of women with a positive HPV self-collected sample who attend follow-up
testing at 30, 60, or 90 days after mail out of the results.
Discussion: The CHOiCE trial will provide strong and important evidence allowing us to determine if and how HPV
self-sampling can be used to increase participation in cervical cancer screening. This trial therefore has the potential to
improve prevention and reduce the number of deaths caused by cervical cancer.
Trial registration: Current Controlled Trials NCT02680262. Registered 10 February 2016.
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Background
Organized screening programs have reduced cervical can-
cer incidence and mortality in many western countries
[1–3]. Yet, the effectiveness of such programs is chal-
lenged by suboptimal participation and coverage [4, 5],
and more than half of all invasive cervical cancers are
diagnosed among women who are under- or unscreened
[6–8]. It is therefore crucial to identify ways to improve
screening participation, e.g. by removing existing barriers
to regular screening.
In the Danish organized screening program, the overall
participation rate, defined as having a screening test
within 365 days after an invitation, is currently 65 % [9].
This percentage has been decreasing slightly in recent
years [9]. Earlier studies show sociodemographic in-
equalities in screening participation [10, 11]. Thus, a
Danish study identify several barriers to participation,
including lack of knowledge about screening and cer-
vical cancer, discomfort during pelvic examinations, fear
of cancer, practicalities in private life, and in access to
testing facilities [12]. Some of these barriers may be
overcome if self-sampling at home is an option which,
however, is not currently the case in the Danish screen-
ing program.
Recent research advocates the use of high-risk human
papillomavirus (hrHPV) testing over cytology because it is
more sensitive in detecting cervical intraepithelial neopla-
sia of grade 2 or worse (CIN2+) and provides better
protection against cervical cancer [13, 14]. Furthermore,
hrHPV testing enables women to self-sample cervico-
vaginal material; self-collected samples have shown sensi-
tivity for detection of CIN2+ that is comparable to that of
clinician-collected samples if validated Polymerase Chain
Reaction (PCR)-tests are used [15, 16]. Self-sampling also
appears to improve screening participation. Hence, a
meta-analysis showed that mailing women a test-kit for
self-sampling at home, including pre-stamped envelopes
for mailing of the sample to a laboratory for HPV testing,
increased screening participation compared with women
receiving standard invitation for regular screening [17].
The participation rate for women offered self-sampling
varies widely among trials, ranging from 10 % [18] to 39 %
[19] with a pooled 12.6 % absolute increase in parti-
cipation compared with standard invitation when self-
sampling kits were mailed directly to all women [17].
Three other trials [20–22] used an opt-in approach for
offering self-sampling, i.e. women were mailed an invita-
tion to order a kit by phone [21], or by mail [20], or to
pick it up at a pharmacy [22]. One of these trials [20]
showed a 12.3 % increase in participation among long-
term non-participants, but the two other trials [21, 22]
showed no positive effect on participation. Moreover, in
the pooled analysis, these trials showed only an insignifi-
cant 0.2 % participation increase compared with women
receiving standard invitations [17]. Thus, more studies
are needed to explore the effect and acceptability associ-
ated with other more timely and modern opt-in ap-
proaches for offering self-sampling (websites, e-mails,
and text messages). To our knowledge, no previous stud-
ies have evaluated the effect on participation of offering
self-sampling, either directly mailed or using timely opt-
in procedures as compared with a standard second
reminder.
Therefore, in the efforts to reduce barriers to cervical
cancer screening and to increase participation, we will
conduct a randomized, controlled effectiveness trial to
evaluate the effect of two different approaches for offer-
ing HPV self-sampling to women who did not partici-
pate in the cervical cancer screening program despite an
invitation and one reminder.
Methods
Trial design
CHOiCE (Cervical HOme-based CancEr screening) is a
parallel, randomized, controlled, open-label trial nested
into a population-based, organized cervical cancer screen-
ing program conducted in the Central Denmark Region.
Women who have not participated in cervical cancer
screening after an invitation and one reminder will be ran-
domly allocated to one of the following three arms (Fig. 1):
1) mailing of a modified second reminder including the
self-sampling kit (intervention group 1)
2) mailing of a modified second reminder informing
the women that they can order the kit either by
e-mail, text message, phone or through a study
webpage (www.hjemme-us.rm.dk) (intervention
group 2)
3) mailing of a standard second reminder (control group)
The modified second reminder informs of the oppor-
tunity to collect a self-sample if wanted, but also about
the opportunity to have a cervical cytology specimen
taken at a general practitioner (GP) (usual procedure).
The standard second reminder informs the women
about the current test opportunity, but contains no in-
formation about self-sampling.
Study setting
Denmark has a total of 5.6 million inhabitants, with 1.5
million women in the target population for cervical
cancer screening [9, 23]. Organized cervical cancer
screening was introduced in the 1960s in some Danish
counties and non-systematically implemented in the rest
of the country until nationwide coverage was achieved
in the late 1990s [24, 25]. The policy and organization of
cervical cancer screening are defined nationally, but the
responsibility for running the screening program lies
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with the regions [26, 27]. Denmark is divided into five
regions one of which is the Central Denmark Region
(23 % of the Danish population) [23, 26].
Since 2007, women aged 23–49 years have been invited
for cervical cancer screening every third year, while women
aged 50–64 years are invited every fifth year [26, 27].
Shortly before 3 or 5 years have passed since a woman’s
last registered cervical cytology result, she is sent an invita-
tion advising her to book an appointment with a GP for a
pelvic examination at which a liquid-based cytology speci-
men is collected [27]. If the responsible Department of
Pathology does not receive a cervical cytology specimen
for analysis, up to two reminders will be sent 3 and
6 months after the initial invitation [27]. Women who do
not respond to invitations or reminders will receive a new
invitation in the next screening round, unless she has
declined participation. For women aged 23–59 years, the
primary screening test is liquid-based cytology; while an
hrHPV-DNA check-out test is recommended for women
aged 60–64 years [26, 27]. In the Danish Cervical Cancer
Screening Program, all testing is free of charge [26, 27].
Routinely, all cervical cytology results, HPV test re-
sults, and histological diagnoses from cervical biopsies
as well all other pathology specimens are registered in
the national Danish Pathology Data Bank (DPDB) under
the woman’s unique Civil Personal Registration (CPR)
number [28–30]. The DPDB also keeps track of which
women are due to receive invitations and reminders to
participate in screening.
In the Central Denmark Region, all samples in the
Cervical Cancer Screening Program are analyzed by the
Department of Pathology, Randers Regional Hospital.
Invitations and reminders are routinely handled by
the Department of Public Health Programs, Randers
Regional Hospital.
Participation and randomization
Participants are restricted to women aged 30 to 64 years
living in the Central Denmark Region who have not par-
ticipated in cervical cancer screening after an invitation
and one reminder. Women who are younger than
30 years are not included due to the low specificity of
HPV DNA tests in younger women [14].
Participants will be identified on a weekly basis in the
nationwide DPDB [28, 29]. The eligible women’s unique
10-digit CPR number [30], including birthdate will be
extracted as this allows us to follow, e.g. the women in
Danish health registers. A CPR number is assigned to
every Danish citizen upon birth [30]. Data will be ex-
tracted in Excel format and transferred to the REDCap
system for storage and automated randomization [31].
Participants will be assigned randomly to the three arms
of the trial in a 1:1:1 ratio as per a computer-generated
randomization schedule following simple randomization
procedures. The CPR number is used for randomization.
The nature of the intervention and allocation ratio pre-
cludes the masking of the participants and study staff.
Interventions
Women in intervention group 1 will be mailed a modi-
fied second reminder, a leaflet entitled Facts, benefits,
and drawbacks about HPV self-sampling and a self-
sampling kit. The leaflet provides information about
HPV and cervical cancer including benefits and draw-
backs of HPV self-sampling compared with regular
screening. The kit includes a brush device (Evelyn Brush,
Rovers Medical Devices B.V, Oss, Netherlands), which
should be used to collect a cervico-vaginal sample for
subsequent hrHPV testing [32], written and drawn instruc-
tions on how to obtain and mail the sample, and a pre-
stamped return envelope addressed to the Department of
Fig. 1 Randomized controlled trial design overview. GP: general practitioner
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Pathology, Randers Regional Hospital, where the hrHPV
testing will be performed. The instructions show how the
woman should label the brush device with an attached la-
boratory specimen barcode. The woman is urged to mail
the return envelope on the day the sample is taken.
Women in intervention group 2 receive the same material
as those in intervention group 1, except for the kit, which
will be mailed to the women only on demand. Additionally,
the leaflet for this group contains information on how to
order the kit (by e-mail, text message, phone, or through a
study webpage (www.hjemme-us.rm.dk). Women in both
intervention groups and in the control group receive the
information that they can contact their GP should they
wish to have a cervical cytology specimen taken.
Analysis of samples
All samples will be handled, processed and analyzed at the
Department of Pathology, Randers Regional Hospital.
The self-collected samples will be handled using the
Cobas® 4800 HPV DNA test (Roche Diagnostics GmBH,
Switzerland) according to the manufacturer’s protocols.
The test identifies HPV16, HPV18 and 12 other hrHPV
types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a
single pool. Results are either 1) hrHPV-negative, 2)
hrHPV-positive (HPV16, HPV18 and/or other hrHPV
types), or 3) unsatisfactory. An unsatisfactory result in-
cludes specimens with a negative β-globin result, a sample
damaged in transit, incorrect labelling, or insufficient ma-
terial for analysis. The hrHPV test results of the self-
collected samples will be registered in the DPDB.
Cervical cytology specimens obtained by GPs will be
analyzed using the standard procedure used in the
Central Denmark Region, i.e. microscopy as the primary
procedure for control group women aged 23–59 years
[27]. In case of detection of Atypical Squamous Cells of
Undetermined Significance (ASC-US) among women
aged ≥ 30 years, an HPV DNA analysis will be performed
using Cobas 4800 [9, 27]. For women aged 60–64 years,
the primary analysis of the cervical cytology is Cobas
4800 HPV DNA analysis, and microscopy will be used
as triage in case of hrHPV-positive test results [9, 27].
When cervical cytology is made as follow-up on hrHPV-
positive test results following self-sampling (see below),
the specimens will be analyzed by microscopy.
Follow up after self-sampling
Women tested by use of self-sampling receive a written
test result by ordinary mail. Approximately 98 % of all
residents in Denmark are listed with a GP [33]. The GP
will also be informed of the testing and the test result.
Women with an hrHPV-positive test results are recom-
mended to visit their GP for a cervical cytology speci-
men within 30 days; and hereafter they will be handled
as described in Danish routine guidelines [27]. Women
with an hrHPV-negative test result will be referred back
to the national screening program and recommended to
participate in the next screening round. Women with an
unsatisfactory sample will receive a second self-sampling
kit and will be encouraged to repeat self-sampling at
home or to visit a GP for a cervical cytology specimen.
Sample size
The sample size was determined by the primary object-
ive (comparison of participation in the intervention and
control groups, respectively) and women will be allo-
cated in equal numbers to the three randomization
groups. Our assumption about participation in the con-
trol group (women who have a cervical cytology speci-
men within 90 days after receiving the standard second
reminder) is 28.7 % [34]. A power calculation (consider-
ing a 2.5 % significance level and 80 % power) based on
finding an expected difference of 3.6 % [35] in participa-
tion between the intervention groups and the control
group shows that the trial will achieve a statistical power
of 80 % if 3109 women are included in each group (a
total of 9327 women).
Data sources and statistical analysis
The DPDB will be used to retrieve data on the CPR
numbers of the study population; participation (yes/no);
if participation was by self-sampling or by visiting a GP;
the hrHPV test results of the self-collected samples, re-
sults of cervical cytology specimens, results of cervical
biopsies and whether appropriate follow-up was con-
ducted (only for self-sampling women). Furthermore,
data on the women’s previous screening history will be
obtained from the DPDB. From Statistics Denmark, in-
formation on sociodemographic status will be obtained
using the women’s CPR number. An overview of the
used data sources and information is seen in Table 1.
The characteristics of the women in the intervention
groups and the control group will accordingly be pre-
sented using descriptive statistics (mean, standard devi-
ation, numbers, or proportions) on sociodemographic
factors (e.g. age, marital status, education level, ethnicity,
income, living in rural or urban area, and occupation)
and previous screening history in order to determine if
the randomization was adequately balanced.
Participation will be defined as a submitted self-
collected sample or having a cervical cytology specimen
within 90 and 180 days after the mailing of second re-
minders. The proportion of women participating in each
group will be calculated, as will the absolute difference
in the participation proportion between the control and
intervention groups and the corresponding 95 % confi-
dence intervals (CIs). The relative risks and 95 % CIs of
having a sample in the intervention groups compared
with the control group will be estimated. Per-protocol
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and intention-to-treat analyses will be performed. The
latter include data on women who were invited to self-
sample, but instead attended regular screening. Participa-
tion will also be reported by age and screening history.
The prevalence of hrHPV cases and histologically con-
firmed CIN lesions in the interventions groups will be
reported. Estimates and 95 % CIs of the proportion of
women with a hrHPV sample who have appropriate
follow-up will also be calculated. Appropriate follow-up
will be defined as having a cervical cytology specimen
taken at 30, 60, or 90 days after mailing of the test result.
Participant timeline
The study will continue until a total of 9327 women
have been invited. The expected study duration, includ-
ing the follow-up period, is 12 months. Kits and re-
minders will be sent out progressively over an estimated
4-month-period starting in March 2016.
Ethical considerations
The study was approved by the Danish Data Protection
Agency (j. no.: 1-16-02-495-15) and by Danish Health
Authorities (j. no.: 3-3013-1407/1). The study has been
presented to The Central Denmark Region Committees
on Health Research Ethics. The Committeesdecided that,
according to the Danish Act on Research Ethics Review
of Health Research Projects (Act number 593 of 14 July
2011),this study should not be notified to the Commit-
tees (j. no.: 1-10-72-259-15).
Included women receive written information about the
self-sampling procedure and the drawbacks and benefits
of self-sampling versus regular screening. Likewise, the
information includes a passage that clearly explains that
if hrHPV is detected, the woman will be referred for
subsequent follow-up testing. Any woman who returns
the self-collected sample hereby expresses her consent
to the analysis of the sample and to receiving any test re-
sults and follow-up recommendations by mail. The
women are also informed that their GP will be informed
of their test result.
Discussion
The Danish Cervical Cancer Screening Program is chal-
lenged by a suboptimal participation rate [9]. Nearly half
(45 %) of all newly diagnosed cervical cancers in
Denmark are found among under-screened women [36].
Numerous other countries are facing a similar situation
[6, 8]. Strategies to improve participation are important
priorities for the Cervical Cancer Screening Program,
and new strategies are needed to target women who
have not participated in cervical cancer screening despite
invitations for regular screening [27]. HPV self-sampling
is a valid screening tool that has the potential to over-
come known barriers to regular screening as evidenced
by trials [18–22, 35, 37–44] showing that self-sampling
can improve screening participation, although the effect
varied substantially between countries. In addition, high
compliance to follow-up recommendations among self-
sample hrHPV-positive women is necessary to achieve
the wanted benefit of the intervention and a meta-
analysis by Verdoodt et al. [17] found that appropriate
follow-up was achieved only in 82 % of women with a
hrHPV-positive test result. Evidence from Denmark is
therefore necessary to inform policy makers before
introducing self-sampling.
The planned study gains validity from the fact that all
Danish women have a unique CPR number and that all
activities in the Danish healthcare system, including
those related to cervical cancer screening, are registered
using this number. This enables linkage to e.g. informa-
tion on previous screening history which allows us to
determine the capacity of self-sampling to recruit under-
or unscreened women. The DPDB is a nationwide
database that holds detailed, highly valid records on all
pathology specimens, including cervical cytologies and
HPV tests of provider-collected and self-collected sam-
ples from all Danish pathology departments [28, 29].
Another strength of the study is that the self-sampling
procedure is embedded directly into a population-based,
well-run organized screening program. Women accept
to have their sample analyzed only by submitting it to
the pathology department. Thus, the routines of this
study can be transferred directly to daily routines with
results that are expected to be similar to those of the
present study. As the Central Denmark Region com-
prises a mix of urban and rural areas, we will also be





Participation by self-sampling or visiting a GP
HrHPV test results of self-collected samples
Dysplasia and/or hrHPV test results of cervical
cytology and histology specimens obtained
in the whole country
Screening history
Age at date of second reminder
Statistic Denmark Marital status
Living in rural or urban area
Education level
Ethnicity (country of birth)
Occupation
Income
All data are registered and collected by use of the unique CPR number which
includes the participant’s date of birth
CPR Civil Personal Registration, GP General Practitioner
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able to disclose whether there are true urban-rural dif-
ferences in the effect of self-sampling as suggested in an
Italian trial [21]. This may, in turn, afford us with better
opportunities for transferring the results to other re-
gions. Furthermore, we include a wider variety of more
timely opt-in approaches than earlier studies using opt-
in approaches [20–22]. This may increase the effect of
this procedure as compared with direct mailing of a test-
kit. Overall, we therefore expect to be able to introduce
an approach that is more cost-effective than earlier de-
scribed approaches.
It is a limitation in our study that we use only one type
of sample device, as differences in participation rates
may hinge on the sample device chosen. However, two
trials [45, 46] have compared the effects of a lavage and
a brush self-sampling device on screening participation.
These trials found a slightly higher participation with
the brush device; i.e. the same brush device as used in
our study. Another limitation is that the intervention is
designed to target only hard-to-reach women by seeking
to overcome barriers related to seeking a physician for a
cervical cytology specimen. Other previously described
barriers [12] are not targeted in this study; but such
barriers will clearly need to be investigated in future
research.
The obtained results will be compared with the results
of other self-sampling trials. Of particular interest is to
study trials performed in countries with organized screen-
ing programs. We will seek to explain any discrepancies in
the results with reference to differences in the study
designs, interventions, study populations, and settings.
As the trial is an effectiveness study nested into a rou-
tine screening program, the findings will provide strong
and important evidence allowing us to determine if and
how HPV self-sampling can be used to improve screen-
ing participation. The trial therefore has the potential to
improve cervical cancer prevention and to reduce the
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